Tolerance Bio

What Tolerance Bio does

Tolerance Bio is a preclinical biopharmaceutical company headquartered in Philadelphia, PA, that develops therapeutic platforms targeting the thymus as the master regulator of immune tolerance. Founded in 2024, the company is pursuing treatments for immune-mediated diseases including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and age-related immune decline. Its stated long-term objective is to increase healthspan by preserving, restoring, and manipulating thymic function. The company has not yet initiated clinical trials and currently operates at a pre-revenue stage.

The company's core technology centers on induced pluripotent stem cell (iPSC)-derived thymic organoids that generate functional thymic tissue capable of supporting in vivo T-cell education. Its pipeline includes three principal modalities: an allogeneic "off-the-shelf" iPSC-based thymus cell therapy platform; bioengineered thymic organoids for T-cell education and tumor burden reduction; and pharmacological thymus therapies designed to delay or prevent thymic involution. Published preclinical data in Cancer Research Communications (October 2025) demonstrated that implanted iPSC-derived thymic organoids enabled in vivo positive selection of human T cells, increased intra-tumoral activated T cells, and significantly reduced tumor burden in humanized melanoma mouse models. The platform is anchored by eight patents in regenerative medicine exclusively licensed from the University of Colorado and the University of Florida, with a granted patent covering thymic organoid generation published in Stem Cell Reports in 2023. In September 2025, the company entered an R&D collaboration with ZipCode Bio — co-founded by Nobel Laureate Drew Weissman — to access SHARP (Single-component Homogeneous Amphiphilic Routed Particles) RNA delivery technology for thymus-targeting mRNA therapeutics, adding a fourth modality to the pipeline.

Tolerance Bio plans to generate revenue from therapeutic product sales following regulatory approval, distributing through standard pharmaceutical channels including specialty pharmacies, hospital buying groups, and direct physician ordering. The company has raised approximately $20.2 million in seed funding across October and December 2024 from a syndicate led by Columbus Venture Partners, with Pacific 8 Ventures, Criteria Bio Ventures, Sessa Capital, BioAdvance, and Ben Franklin Technology Partners participating. Beyond Celiac Investments provided additional non-dilutive funding in June 2026 for celiac disease program development. Management is led by CEO Francisco Leon, MD, PhD, who previously co-led development and approval of teplizumab (TZIELD) through Provention Bio's acquisition by Sanofi, and CFO Justin Vogel, who has raised over $1.3 billion across prior biotech transactions.

Name

Tolerance Bio

Legal name

Tolerance Bio, Inc.

Website

https://tolerancebio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Tolerance Bio is a preclinical Philadelphia-based biopharmaceutical company developing iPSC-derived thymic organoid, allogeneic cell therapy, pharmacological, and mRNA platforms to restore and manipulate immune tolerance for cancer, autoimmunity, transplant rejection, and age-related immune decline.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAGAL

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAABAF

Dendritic Cell & Other APC-based Therapies

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAAEAB

Therapeutic Vaccines (cancer, chronic infection immunotherapy)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

• Cell therapy platform
• Thymus-based therapeutics
• Immune tolerance restoration
• IPSC-derived organoids
• Immunology biopharmaceuticals

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Thymus Cell Therapy Products: Pre-revenue biopharmaceutical company developing allogeneic iPSC-based thymus cell therapy products for immune-mediated diseases. Revenue will be generated through therapeutic product sales upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Tolerance Bio is a preclinical-stage biopharmaceutical company developing a multi-modality therapeutic platform that preserves, restores, and manipulates thymus function to treat immune-mediated diseases. The company's core offerings include an allogeneic iPSC-based thymus cell therapy platform, iPSC-derived thymic organoids that support functional T-cell education in vivo, and pharmacological thymus therapies to delay or prevent thymic involution. Target indications include cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.

Product overview

Tolerance Bio is a biopharmaceutical company developing a multi-modality therapeutic platform focused on preserving, restoring, and manipulating thymus function to address immune-mediated diseases. The company's core offerings include: (1) an allogeneic 'off the shelf' iPSC-based thymus cell therapy platform for treating conditions like cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies; (2) iPSC-derived thymic organoids for T-cell education and potential cancer therapy; (3) pharmacological thymus therapies to delay or prevent thymic involution; and (4) pipeline programs including monoclonal antibodies, mRNA therapeutics, and cell therapies targeting the thymus for celiac disease, immune aging, and autoimmunity.

Differentiator

Problem solved

Functional benefit

Products and services

• Allogeneic iPSC-based Thymus Cell Therapy Platform An 'off the shelf' cell therapy platform using induced pluripotent stem cells (iPSCs) to generate thymic cells for treating immune-mediated diseases including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.
• iPSC-derived Thymic Organoids Bio-engineered thymus tissue generated from patient-specific iPSCs through direct differentiation, used for T-cell education and tumor burden reduction in melanoma models, with potential as a cell therapy for cancer and improved patient-derived xenograft models for personalized medicine.
• Pharmacological Thymus Therapies Small molecule or biologic approaches designed to delay, prevent, or restore thymic function for treating acute and age-related thymic involution, addressing immune diseases through thymus preservation and regeneration.
• mRNA Thymus Therapeutics mRNA-based approaches for targeting the thymus to restore immune tolerance, being developed in collaboration with ZipCode Bio using SHARP delivery technology for immune aging and autoimmunity.
• Monoclonal Antibodies for Celiac Disease Monoclonal antibody-based approach targeting the thymus to restore immune tolerance for celiac disease treatment, part of BCI investment-supported early development program.

Quantifiable outcome

• Tumors grew significantly slower in mice with human thymic tissue compared to controls in melanoma xenograft model
• +3 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• ZipCode BiocoreStrategic or Co-development Partner · 8 September 2025Strategic R&D collaboration to pioneer novel delivery methods for targeted thymus therapeutics. Combines Tolerance Bio's thymus biology expertise with ZipCode Bio's SHARP (Single-component Homogeneous Amphiphilic Routed Particles) RNA delivery technology. Jointly developing thymus-targeting therapeutics for immune aging and autoimmunity. ZipCode Bio, co-founded by Nobel Laureate Drew Weissman, leads development of thymus-targeting SHARPs while Tolerance Bio advances translation into disease models.
• University of FloridacoreStrategic or Co-development PartnerResearch partner where Scientific Co-Founder Dr. Holger Russ is Associate Professor in the Department of Pharmacology and Therapeutics at the Diabetes Institute. Technology for generating functional thymic and pancreatic islets from pluripotent stem cells was initially developed at this institution.
• University of Colorado AnschutzcoreStrategic or Co-development PartnerResearch partner where thymic organoid research was led by Dr. Antonio Jimeno, M.D., Ph.D. at the Division of Medical Oncology. University of Colorado has filed patent applications based on thymic organoid results, exclusively licensed to Tolerance Bio.
• University of TartuminorStrategic or Co-development PartnerInternational research partner in Estonia collaborating on thymus-related research initiatives.
• Diabetes Research InstituteminorStrategic or Co-development PartnerResearch partner focused on diabetes and cellular transplantation research. Scientific Advisory Board member Dr. Camillo Ricordi serves as Director Emeritus of the Diabetes Research Institute at University of Miami.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Thymmune Therapeutics: Direct peer developing iPSC-derived thymic cell therapies to restore immune function; operates in the same thymus-centric modality space as Tolerance Bio and targets overlapping indications including immune aging.
• Fate Therapeutics: iPSC-derived NK and T-cell therapy company with a clinical-stage allogeneic cell therapy platform; comparable to Tolerance Bio's allogeneic iPSC-based thymus cell therapy approach in modality and manufacturing.
• Century Therapeutics: iPSC-derived allogeneic cell therapies engineered with multiple modalities (CAR, TCR, NK); comparable in iPSC platform architecture and immune-cell engineering approach.
• Sonoma Biotherapeutics: Treg-based cell therapies for autoimmune and inflammatory disease; directly comparable to Tolerance Bio's immune tolerance restoration thesis via engineered immune cells.
• Vor Biopharma: Engineered hematopoietic stem cell therapies designed to enable targeted cancer treatment while protecting healthy cells; comparable in cell engineering platform and immune modulation thesis.
• HebeCell Corporation: iPSC-derived NK cell therapy company; comparable in iPSC-derived cell therapy platform and bioanalytical approaches, with leadership overlap (Carina Meyer led assay development at HebeCell).

Broad incumbents

• Allogene Therapeutics: Leading clinical-stage allogeneic CAR T-cell therapy company; broader incumbent in allogeneic cell therapy manufacturing and immunology with overlap in iPSC and gene-edited cell approaches.
• Beam Therapeutics: Clinical-stage base editing company with iPSC-derived cell therapy programs; comparable in iPSC cell therapy engineering, with leadership overlap (Yeh-Chuin Poh previously at Beam).

Others

• Provention Bio (acquired by Sanofi): Immunology biotech that developed and commercialized teplizumab (TZIELD) for Type 1 diabetes; directly comparable via overlapping leadership (CEO Francisco Leon, CFO Justin Vogel, CBO Phil Ball) and indication overlap in immune-mediated diseases.
• Semma Therapeutics (acquired by Vertex): Stem cell-derived pancreatic beta-cell therapy company acquired by Vertex; comparable in iPSC-derived cell therapy approach, with leadership overlap (Yeh-Chuin Poh led stem cell-derived beta cell development at Semma).

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tolerance-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tolerance Bio